Status:
RECRUITING
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
Lead Sponsor:
Anterogen Co., Ltd.
Conditions:
Crohn Disease
Eligibility:
All Genders
18-65 years
Brief Summary
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
Detailed Description
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months. ALLO-ASC-CD is intravenous infusion...
Eligibility Criteria
Inclusion Criteria:
- Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101.
- Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.
Exclusion Criteria:
1. Subjects who are considered not suitable for the study by the principal investigator.
Key Trial Info
Start Date :
November 16 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03183661
Start Date
November 16 2016
End Date
December 31 2026
Last Update
August 25 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080
2
Severance Hospital
Seoul, South Korea, 03722